Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Report 2026

Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Overview

• Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf market size has reached to $3.89 billion in 2025 • Expected to grow to $5.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: The Increasing Incidence Of Neutropenia Is Fueling Market Growth Due To Rising Prevalence Of Immunocompromised Patients • Market Trend: Next-Generation Treatments Reduce Injection Frequency And Improve Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market?

Recombinant human granulocyte colony-stimulating factor injection (RHGCSF) refers to a biologic medicinal product formulated to stimulate the production and maturation of neutrophils in the bone marrow, thereby strengthening the immune system. It contains a recombinant form of human granulocyte colony-stimulating factor that helps reduce the risk of infection in patients with neutropenia caused by chemotherapy, Bone Marrow Transplantation, or certain hematological disorders. The main types of recombinant human granulocyte colony-stimulating factor injections RHGCF include filgrastim and lenograstim. Filgrastim refers to a recombinant protein that stimulates the production of neutrophils to prevent or treat neutropenia in patients undergoing chemotherapy or bone marrow transplantation. These injections are administered via routes such as subcutaneous injection and intravenous injection. They are used for patient types including pediatric patients and adult patients. They are applied across indications such as cancer and bone marrow disorders, and are distributed through hospital pharmacies and retail pharmacies.

What Is The Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Growth Forecast?

The recombinant human granulocyte colonystimulating factor injection rhgcsf market size is expected to see strong growth in the next few years. It will grow to $5.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growing cancer prevalence rates, higher demand for long acting injectables, expansion of biosimilar drug approvals, rising access to specialty biologics, increasing hospital supportive care protocols. Major trends in the forecast period include growth in biosimilar GCSF injections, expansion of prefilled syringe formats, higher adoption in chemotherapy support care, long acting pegylated formulation demand, increased combination supportive therapy use.

Global Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Segmentation

1) By Type: Filgrastim; Lenograstim 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection 3) By Patient Type: Pediatric Patients; Adult Patients 4) By Application: Cancer; Bone Marrow Disorders 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies Subsegments: 1) By Filgrastim: Neupogen; Zarxio; Accofil; Granix 2) By Lenograstim: Neutrogin; Lenograstim Biosimilar; Lenograstim Standard Formulation; Lenograstim Lyophilized Powder

What Is The Driver Of The Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market?

The increasing incidence of neutropenia is expected to propel the growth of the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market going forward. Neutropenia is a medical condition characterized by abnormally low levels of neutrophils, a type of white blood cell essential for fighting infections, making individuals highly susceptible to bacterial and fungal infections. The incidence of neutropenia is rising primarily due to the growing use of intensive chemotherapy regimens for cancer treatment, as modern oncology protocols employ more aggressive dosing schedules to improve patient survival rates, which consequently increases the frequency and severity of chemotherapy-induced bone marrow suppression. Recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) supports neutropenia by stimulating the bone marrow to proliferate and differentiate neutrophil precursors, accelerating the release of mature neutrophils into the bloodstream, thereby reducing the duration and severity of neutropenia and lowering the risk of infection in affected patients. For instance, in February 2025, the UK Health Security Agency (UKHSA), a UK-based government agency, reported that febrile neutropenia (FN) or other manifestations of infection in immunocompromised hosts without a clear anatomical site accounted for 206 cases, representing 1.4% of all diagnoses in the community setting. Therefore, the increasing incidence of neutropenia is driving the growth of the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market.

Key Players In The Global Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market

Major companies operating in the recombinant human granulocyte colonystimulating factor injection rhgcsf market are Pfizer Inc., Novartis AG, Amgen Inc., Intas Pharmaceuticals Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Pharmaceuticals Ltd., Biocon Limited, North China Pharmaceutical Group Corporation, Shijiazhuang Pharmaceutical Group Co. Ltd., Emcure Pharmaceuticals Ltd., Harbin Pharmaceutical Group Co. Ltd., Reliance Life Sciences Pvt. Ltd., Jiuyuan Gene Engineering Co. Ltd., Qilu Pharmaceutical Co. Ltd., Amoytop Biotech Co. Ltd., Kexing Biopharm Co. Ltd., Sunway Biotech Co. Ltd., Apotex Inc., and Wuzhong Pharmaceutical Group Co. Ltd.

Global Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Trends and Insights

Major companies operating in the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market are focusing on developing innovative formulations such as PEG-free recombinant G-CSF fusion proteins to extend drug half-life, reduce injection frequency, and improve patient compliance while effectively preventing chemotherapy-induced neutropenia. PEG-free recombinant G-CSF fusion proteins are engineered molecules that combine G-CSF with a human Fc fragment without using polyethylene glycol (PEG), which extends the drug’s half-life, enhances stability, and reduces injection frequency, thereby improving patient compliance and effectively boosting neutrophil production to prevent chemotherapy-induced neutropenia. For instance, in November 2024, Evive Biotech Co. Ltd., a China-based biopharmaceutical company, and APOGEPHA Arzneimittel GmbH, a Germany-based pharmaceutical company, launched Ryzneuta (Efbemalenograstim alfa Injection), an innovative long-acting, PEG-free rhG-CSF product in the German market. Ryzneuta is produced using Chinese Hamster Ovary (CHO) cells, ensuring a mammalian glycosylation pattern, and functions by binding to the G-CSF receptor to stimulate survival, proliferation, and differentiation of neutrophil precursors and mature neutrophils. Its unique Fc-fusion design extends its half-life, reduces injection frequency, and strengthens immune function, helping to prevent chemotherapy dose reductions or delays. The product has demonstrated efficacy and safety across multi-center, randomized, active-controlled trials and represents a significant advancement over conventional rhG-CSF injections.

What Are Latest Mergers And Acquisitions In The Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market?

In April 2023, Assertio Holdings Inc., a US-based specialty pharmaceutical company, acquired Spectrum Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, Assertio aims to expand its commercial capabilities and diversify its therapeutic portfolio by combining digital and in-person sales channels to accelerate product launches and revenue growth. Spectrum Pharmaceuticals Inc. is a US-based commercial-stage biopharmaceutical company that specializes in developing and commercializing novel oncology therapies, including the long-acting G-CSF product ROLVEDON.

Regional Insights

North America was the largest region in the recombinant human granulocyte colony-stimulating factor injection (rhG-CSF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market?

The recombinant human granulocyte colony-stimulating factor injection (RHGCSF) market consists of sales of injectable formulations, prefilled syringes, filgrastim injections, pegfilgrastim injections, lenograstim injections, biosimilar filgrastim injections, and biosimilar pegfilgrastim injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Recombinant Human Granulocyte Colonystimulating Factor Injection Rhgcsf Market Report 2026?

The recombinant human granulocyte colonystimulating factor injection rhgcsf market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant human granulocyte colonystimulating factor injection rhgcsf industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.